Calliditas Therapeutics AB
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Calliditas Therapeutics AB
First-in-class iptacopan could help Novartis expand into kidney disease, and take on Alexion’s blockbuster rare disease franchise.
Calliditas Therapeutics' lead product candidate Nefecon will be fast-tracked at the EMA once the marketing application is filed. Takeda and Bayer are hoping for the same success with maribavir and copanlisib respectively.
Takeda, Calliditas and Bayer are set to learn whether the European Medicines Agency will grant their respective products accelerated assessment status when they file for pan-EU marketing approval.
Interview: delivering on its US business strategy during the COVID-19 pandemic has required a focus on communication, according to Calliditas CEO Renee Aguiar-Lucander.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Pharmalink AB